Loading…
Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease
Background: To evaluate the impact of the extent of coronary disease (single- or multivessel) and of fluvastatin treatment on the incidence of long-term cardiac atherosclerotic complications in the Lescol Intervention Prevention Study (LIPS). Methods: A total of 1063 patients with single-vessel dise...
Saved in:
| Published in: | International journal of cardiology 2005-02, Vol.98 (3), p.479-486 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c415t-effe2fc50bb52e8148b2bf6b015d9006ed3acc9a6a47d7ff229c47cd083cbc7d3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c415t-effe2fc50bb52e8148b2bf6b015d9006ed3acc9a6a47d7ff229c47cd083cbc7d3 |
| container_end_page | 486 |
| container_issue | 3 |
| container_start_page | 479 |
| container_title | International journal of cardiology |
| container_volume | 98 |
| creator | Lemos, Pedro A. de Feyter, Pim J. Serruys, Patrick W. Saia, Francesco Arampatzis, Chourmouzios A. Disco, Clemens Mercado, Nestor Mainar, Vicente Morı́s, César van den Bos, A.A. Berghoefer, Gunnar |
| description | Background: To evaluate the impact of the extent of coronary disease (single- or multivessel) and of fluvastatin treatment on the incidence of long-term cardiac atherosclerotic complications in the Lescol Intervention Prevention Study (LIPS).
Methods: A total of 1063 patients with single-vessel disease and 614 patients with multivessel disease were randomized to receive fluvastatin (40 mg bid) or placebo for at least 3 years following a first successful percutaneous coronary intervention. The incidence of cardiac atherosclerotic events (cardiac death, non-fatal myocardial infarction, and coronary re-interventions not related to restenosis) was evaluated.
Results: Patients with multivessel disease tended to be older and presented a higher prevalence of associated risk factors and cardiovascular antecedents. The presence of multivessel disease markedly increased the risk of cardiac atherosclerotic events compared with single-vessel disease among patients allocated to placebo (RR 1.67 [95% CI: 1.24–2.25];
p |
| doi_str_mv | 10.1016/j.ijcard.2003.11.031 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67421965</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167527304001445</els_id><sourcerecordid>67421965</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-effe2fc50bb52e8148b2bf6b015d9006ed3acc9a6a47d7ff229c47cd083cbc7d3</originalsourceid><addsrcrecordid>eNp90E1v1DAQgGELgdql9B8g5AvcEuzEjp0LEqooIFWCQ3u2nPFY9ZL9wONs1X-PV7tSb5x8eWbGehl7L0UrhRw-r9u0Bp9D2wnRt1K2opev2EpaoxpptHrNVpWZRnemv2RvidZCCDWO9oJdSm2ElbZfsd-383LwVHxJW54xLIDEyyNy1Tyjz_x4IXngOdEfXsm-QtwW4k-pPPLNMpd0QCKceUiEnvAdexP9THh9fq_Yw-23-5sfzd2v7z9vvt41oKQuDcaIXQQtpkl3aKWyUzfFYRJSh1GIAUPvAUY_eGWCibHrRlAGgrA9TGBCf8U-nfbu8-7vglTcJhHgPPst7hZyg1GdHAddoTpByDuijNHtc9r4_OykcMeSbu1OJd2xpJPS1ZJ17MN5_zJtMLwMndNV8PEMPIGfY_ZbSPTiBq2tHVV1X04Oa41DwuwIakLAkDJCcWGX_v-Tf7dnlMM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67421965</pqid></control><display><type>article</type><title>Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease</title><source>ScienceDirect Journals</source><creator>Lemos, Pedro A. ; de Feyter, Pim J. ; Serruys, Patrick W. ; Saia, Francesco ; Arampatzis, Chourmouzios A. ; Disco, Clemens ; Mercado, Nestor ; Mainar, Vicente ; Morı́s, César ; van den Bos, A.A. ; Berghoefer, Gunnar</creator><creatorcontrib>Lemos, Pedro A. ; de Feyter, Pim J. ; Serruys, Patrick W. ; Saia, Francesco ; Arampatzis, Chourmouzios A. ; Disco, Clemens ; Mercado, Nestor ; Mainar, Vicente ; Morı́s, César ; van den Bos, A.A. ; Berghoefer, Gunnar</creatorcontrib><description>Background: To evaluate the impact of the extent of coronary disease (single- or multivessel) and of fluvastatin treatment on the incidence of long-term cardiac atherosclerotic complications in the Lescol Intervention Prevention Study (LIPS).
Methods: A total of 1063 patients with single-vessel disease and 614 patients with multivessel disease were randomized to receive fluvastatin (40 mg bid) or placebo for at least 3 years following a first successful percutaneous coronary intervention. The incidence of cardiac atherosclerotic events (cardiac death, non-fatal myocardial infarction, and coronary re-interventions not related to restenosis) was evaluated.
Results: Patients with multivessel disease tended to be older and presented a higher prevalence of associated risk factors and cardiovascular antecedents. The presence of multivessel disease markedly increased the risk of cardiac atherosclerotic events compared with single-vessel disease among patients allocated to placebo (RR 1.67 [95% CI: 1.24–2.25];
p<0.001). In patients treated with fluvastatin, however, no significant differences in long-term outcomes were observed between patients with multivessel disease and patients single-vessel disease (RR 1.28 [95% CI: 0.90–1.81];
p=0.2).
Conclusions: Multivessel coronary disease impaired the 4-year outcomes after percutaneous intervention. However, the hazardous effect of multivessel disease was significantly reduced by long-term fluvastatin treatment.</description><identifier>ISSN: 0167-5273</identifier><identifier>EISSN: 1874-1754</identifier><identifier>DOI: 10.1016/j.ijcard.2003.11.031</identifier><identifier>PMID: 15708183</identifier><identifier>CODEN: IJCDD5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Angioplasty ; Angioplasty, Balloon, Coronary ; Biological and medical sciences ; Cardiology. Vascular system ; Cholesterol ; Coronary Artery Disease - epidemiology ; Coronary disease ; Coronary Disease - drug therapy ; Coronary Disease - therapy ; Coronary heart disease ; Fatty Acids, Monounsaturated - therapeutic use ; Heart ; HMG-CoA reductase inhibitors ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Indoles - therapeutic use ; Medical sciences ; Proportional Hazards Models ; Risk Assessment ; Stents</subject><ispartof>International journal of cardiology, 2005-02, Vol.98 (3), p.479-486</ispartof><rights>2004 Elsevier Ireland Ltd</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-effe2fc50bb52e8148b2bf6b015d9006ed3acc9a6a47d7ff229c47cd083cbc7d3</citedby><cites>FETCH-LOGICAL-c415t-effe2fc50bb52e8148b2bf6b015d9006ed3acc9a6a47d7ff229c47cd083cbc7d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16558894$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15708183$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lemos, Pedro A.</creatorcontrib><creatorcontrib>de Feyter, Pim J.</creatorcontrib><creatorcontrib>Serruys, Patrick W.</creatorcontrib><creatorcontrib>Saia, Francesco</creatorcontrib><creatorcontrib>Arampatzis, Chourmouzios A.</creatorcontrib><creatorcontrib>Disco, Clemens</creatorcontrib><creatorcontrib>Mercado, Nestor</creatorcontrib><creatorcontrib>Mainar, Vicente</creatorcontrib><creatorcontrib>Morı́s, César</creatorcontrib><creatorcontrib>van den Bos, A.A.</creatorcontrib><creatorcontrib>Berghoefer, Gunnar</creatorcontrib><title>Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease</title><title>International journal of cardiology</title><addtitle>Int J Cardiol</addtitle><description>Background: To evaluate the impact of the extent of coronary disease (single- or multivessel) and of fluvastatin treatment on the incidence of long-term cardiac atherosclerotic complications in the Lescol Intervention Prevention Study (LIPS).
Methods: A total of 1063 patients with single-vessel disease and 614 patients with multivessel disease were randomized to receive fluvastatin (40 mg bid) or placebo for at least 3 years following a first successful percutaneous coronary intervention. The incidence of cardiac atherosclerotic events (cardiac death, non-fatal myocardial infarction, and coronary re-interventions not related to restenosis) was evaluated.
Results: Patients with multivessel disease tended to be older and presented a higher prevalence of associated risk factors and cardiovascular antecedents. The presence of multivessel disease markedly increased the risk of cardiac atherosclerotic events compared with single-vessel disease among patients allocated to placebo (RR 1.67 [95% CI: 1.24–2.25];
p<0.001). In patients treated with fluvastatin, however, no significant differences in long-term outcomes were observed between patients with multivessel disease and patients single-vessel disease (RR 1.28 [95% CI: 0.90–1.81];
p=0.2).
Conclusions: Multivessel coronary disease impaired the 4-year outcomes after percutaneous intervention. However, the hazardous effect of multivessel disease was significantly reduced by long-term fluvastatin treatment.</description><subject>Angioplasty</subject><subject>Angioplasty, Balloon, Coronary</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Cholesterol</subject><subject>Coronary Artery Disease - epidemiology</subject><subject>Coronary disease</subject><subject>Coronary Disease - drug therapy</subject><subject>Coronary Disease - therapy</subject><subject>Coronary heart disease</subject><subject>Fatty Acids, Monounsaturated - therapeutic use</subject><subject>Heart</subject><subject>HMG-CoA reductase inhibitors</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Indoles - therapeutic use</subject><subject>Medical sciences</subject><subject>Proportional Hazards Models</subject><subject>Risk Assessment</subject><subject>Stents</subject><issn>0167-5273</issn><issn>1874-1754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNp90E1v1DAQgGELgdql9B8g5AvcEuzEjp0LEqooIFWCQ3u2nPFY9ZL9wONs1X-PV7tSb5x8eWbGehl7L0UrhRw-r9u0Bp9D2wnRt1K2opev2EpaoxpptHrNVpWZRnemv2RvidZCCDWO9oJdSm2ElbZfsd-383LwVHxJW54xLIDEyyNy1Tyjz_x4IXngOdEfXsm-QtwW4k-pPPLNMpd0QCKceUiEnvAdexP9THh9fq_Yw-23-5sfzd2v7z9vvt41oKQuDcaIXQQtpkl3aKWyUzfFYRJSh1GIAUPvAUY_eGWCibHrRlAGgrA9TGBCf8U-nfbu8-7vglTcJhHgPPst7hZyg1GdHAddoTpByDuijNHtc9r4_OykcMeSbu1OJd2xpJPS1ZJ17MN5_zJtMLwMndNV8PEMPIGfY_ZbSPTiBq2tHVV1X04Oa41DwuwIakLAkDJCcWGX_v-Tf7dnlMM</recordid><startdate>20050228</startdate><enddate>20050228</enddate><creator>Lemos, Pedro A.</creator><creator>de Feyter, Pim J.</creator><creator>Serruys, Patrick W.</creator><creator>Saia, Francesco</creator><creator>Arampatzis, Chourmouzios A.</creator><creator>Disco, Clemens</creator><creator>Mercado, Nestor</creator><creator>Mainar, Vicente</creator><creator>Morı́s, César</creator><creator>van den Bos, A.A.</creator><creator>Berghoefer, Gunnar</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050228</creationdate><title>Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease</title><author>Lemos, Pedro A. ; de Feyter, Pim J. ; Serruys, Patrick W. ; Saia, Francesco ; Arampatzis, Chourmouzios A. ; Disco, Clemens ; Mercado, Nestor ; Mainar, Vicente ; Morı́s, César ; van den Bos, A.A. ; Berghoefer, Gunnar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-effe2fc50bb52e8148b2bf6b015d9006ed3acc9a6a47d7ff229c47cd083cbc7d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Angioplasty</topic><topic>Angioplasty, Balloon, Coronary</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Cholesterol</topic><topic>Coronary Artery Disease - epidemiology</topic><topic>Coronary disease</topic><topic>Coronary Disease - drug therapy</topic><topic>Coronary Disease - therapy</topic><topic>Coronary heart disease</topic><topic>Fatty Acids, Monounsaturated - therapeutic use</topic><topic>Heart</topic><topic>HMG-CoA reductase inhibitors</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Indoles - therapeutic use</topic><topic>Medical sciences</topic><topic>Proportional Hazards Models</topic><topic>Risk Assessment</topic><topic>Stents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lemos, Pedro A.</creatorcontrib><creatorcontrib>de Feyter, Pim J.</creatorcontrib><creatorcontrib>Serruys, Patrick W.</creatorcontrib><creatorcontrib>Saia, Francesco</creatorcontrib><creatorcontrib>Arampatzis, Chourmouzios A.</creatorcontrib><creatorcontrib>Disco, Clemens</creatorcontrib><creatorcontrib>Mercado, Nestor</creatorcontrib><creatorcontrib>Mainar, Vicente</creatorcontrib><creatorcontrib>Morı́s, César</creatorcontrib><creatorcontrib>van den Bos, A.A.</creatorcontrib><creatorcontrib>Berghoefer, Gunnar</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lemos, Pedro A.</au><au>de Feyter, Pim J.</au><au>Serruys, Patrick W.</au><au>Saia, Francesco</au><au>Arampatzis, Chourmouzios A.</au><au>Disco, Clemens</au><au>Mercado, Nestor</au><au>Mainar, Vicente</au><au>Morı́s, César</au><au>van den Bos, A.A.</au><au>Berghoefer, Gunnar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease</atitle><jtitle>International journal of cardiology</jtitle><addtitle>Int J Cardiol</addtitle><date>2005-02-28</date><risdate>2005</risdate><volume>98</volume><issue>3</issue><spage>479</spage><epage>486</epage><pages>479-486</pages><issn>0167-5273</issn><eissn>1874-1754</eissn><coden>IJCDD5</coden><abstract>Background: To evaluate the impact of the extent of coronary disease (single- or multivessel) and of fluvastatin treatment on the incidence of long-term cardiac atherosclerotic complications in the Lescol Intervention Prevention Study (LIPS).
Methods: A total of 1063 patients with single-vessel disease and 614 patients with multivessel disease were randomized to receive fluvastatin (40 mg bid) or placebo for at least 3 years following a first successful percutaneous coronary intervention. The incidence of cardiac atherosclerotic events (cardiac death, non-fatal myocardial infarction, and coronary re-interventions not related to restenosis) was evaluated.
Results: Patients with multivessel disease tended to be older and presented a higher prevalence of associated risk factors and cardiovascular antecedents. The presence of multivessel disease markedly increased the risk of cardiac atherosclerotic events compared with single-vessel disease among patients allocated to placebo (RR 1.67 [95% CI: 1.24–2.25];
p<0.001). In patients treated with fluvastatin, however, no significant differences in long-term outcomes were observed between patients with multivessel disease and patients single-vessel disease (RR 1.28 [95% CI: 0.90–1.81];
p=0.2).
Conclusions: Multivessel coronary disease impaired the 4-year outcomes after percutaneous intervention. However, the hazardous effect of multivessel disease was significantly reduced by long-term fluvastatin treatment.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>15708183</pmid><doi>10.1016/j.ijcard.2003.11.031</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-5273 |
| ispartof | International journal of cardiology, 2005-02, Vol.98 (3), p.479-486 |
| issn | 0167-5273 1874-1754 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67421965 |
| source | ScienceDirect Journals |
| subjects | Angioplasty Angioplasty, Balloon, Coronary Biological and medical sciences Cardiology. Vascular system Cholesterol Coronary Artery Disease - epidemiology Coronary disease Coronary Disease - drug therapy Coronary Disease - therapy Coronary heart disease Fatty Acids, Monounsaturated - therapeutic use Heart HMG-CoA reductase inhibitors Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Indoles - therapeutic use Medical sciences Proportional Hazards Models Risk Assessment Stents |
| title | Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T10%3A59%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fluvastatin%20reduces%20the%204-year%20cardiac%20risk%20in%20patients%20with%20multivessel%20disease&rft.jtitle=International%20journal%20of%20cardiology&rft.au=Lemos,%20Pedro%20A.&rft.date=2005-02-28&rft.volume=98&rft.issue=3&rft.spage=479&rft.epage=486&rft.pages=479-486&rft.issn=0167-5273&rft.eissn=1874-1754&rft.coden=IJCDD5&rft_id=info:doi/10.1016/j.ijcard.2003.11.031&rft_dat=%3Cproquest_cross%3E67421965%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c415t-effe2fc50bb52e8148b2bf6b015d9006ed3acc9a6a47d7ff229c47cd083cbc7d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67421965&rft_id=info:pmid/15708183&rfr_iscdi=true |